Humanized IgG1 anti-CD20 monoclonal antibody that selectively depletes CD20+ B cells via ADCC, CDC, and apoptosis, reducing B‑cell antigen presentation, proinflammatory cytokines, and autoantibody production to dampen B–T cell interactions and CNS inflammation in MS. Also known as RO4964913.
Humanized IgG1 anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20+ B cells via ADCC, complement-dependent cytotoxicity, and apoptosis; reduces B-cell antigen presentation, cytokine and autoantibody production, dampening B–T cell interactions and neuroinflammation.
Ocrelizumab binds CD20 on B cells and triggers Fc-mediated ADCC/phagocytosis by immune effectors and complement-dependent cytotoxicity; it can also induce apoptosis, leading to depletion of CD20+ cells.
Ianalumab (VAY736) is a fully human monoclonal IgG1 antibody that targets the BAFF receptor (BAFF-R; TNFRSF13C) on B cells, blocking BAFF/BLyS survival signaling and inducing antibody-dependent cellular cytotoxicity to deplete B cells. Administered subcutaneously to reduce autoreactive B-cell activity and autoantibody production in diffuse cutaneous systemic sclerosis.
Fully human IgG1 monoclonal antibody against BAFF-R (TNFRSF13C) on B cells that blocks BAFF/BLyS survival signaling and induces Fc-mediated cytotoxicity (e.g., ADCC), resulting in B-cell depletion and reduced autoreactive B-cell activity and autoantibody production.
Ianalumab binds BAFF-R on B cells and engages Fc gamma receptors on effector cells to trigger ADCC, killing BAFF-R–positive cells; blockade of BAFF survival signaling also promotes apoptosis.
HER2-targeted biparatopic antibody–drug conjugate (ADC) that binds two non-overlapping HER2 extracellular epitopes (ECD2 and ECD4), enhances receptor internalization and downregulates surface HER2 to provide dual HER2 signaling blockade while delivering a cytotoxic payload.
TQB2102 is a HER2-directed biparatopic antibody-drug conjugate that binds two non-overlapping HER2 extracellular epitopes (ECD2 and ECD4), drives receptor internalization and surface HER2 downregulation to block HER2 signaling, and releases an intracellular cytotoxic payload to kill HER2-expressing tumor cells.
HER2-directed ADC binds HER2, is internalized, and releases an intracellular cytotoxic payload that kills the HER2-expressing cell (with additional HER2 signaling blockade).
An intravenous glyco-humanized polyclonal (polyspecific) antibody engineered for human-like glycosylation and multi-epitope binding to malignant T-cell surface antigens, aiming to eliminate tumor T cells via Fc-mediated effector functions (ADCC, CDC) and potential direct neutralization in PTCL subtypes.
Glyco-humanized polyspecific polyclonal antibody that binds multiple surface antigens on malignant T cells and induces their elimination via Fc-mediated effector functions (enhanced ADCC through FcγR-expressing NK cells/macrophages and complement-dependent cytotoxicity), with possible direct neutralization of target cells.
Antibody binds malignant T‑cell surface antigens and recruits immune effector functions: Fc gamma receptor–mediated ADCC by NK cells/macrophages and complement-dependent cytotoxicity (CDC), leading to lysis/elimination of the bound target cells.
Humanized, afucosylated IgG1 monoclonal antibody that antagonizes the OX40 (CD134) costimulatory receptor and can deplete OX40+ activated T cells via ADCC, reducing T-cell activation, survival, memory, and type 2 inflammation relevant to atopic dermatitis. Administered as a single subcutaneous dose (via vial or prefilled syringe).
Humanized, afucosylated IgG1 monoclonal antibody against OX40 (CD134) that blocks OX40–OX40L costimulatory signaling and, via enhanced Fc-mediated ADCC, depletes OX40+ activated T cells, thereby reducing T‑cell activation, survival/memory, and type 2 inflammatory responses.
Afucosylated IgG1 anti-OX40 engages Fc receptors (e.g., FcγRIIIa) on NK cells to trigger ADCC, with possible macrophage ADCP, depleting OX40+ activated T cells.